Emerging therapies for food allergy

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 1880-1886

  Keet, Corinne A ^a   Wood, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TALIZUMAB;

ALLERGIC DISEASE; AMINO ACID SUBSTITUTION; CLINICAL PRACTICE; DESENSITIZATION; FOOD ALLERGY; HELMINTH; HERBAL MEDICINE; HUMAN; IMMUNOLOGICAL TOLERANCE; LONG TERM CARE; NONHUMAN; ORAL IMMUNOTHERAPY; PATHOPHYSIOLOGY; PATIENT PREFERENCE; PEANUT ALLERGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SUBLINGUAL IMMUNOTHERAPY;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; DRUGS, CHINESE HERBAL; FOOD HYPERSENSITIVITY; HUMANS; SUBLINGUAL IMMUNOTHERAPY; THERAPY WITH HELMINTHS; VACCINES, DNA;

EID: 84899739540     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72061     Document Type: Review

References (126)

1. Boyce JA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 suppl):S1-S58.
2. Neuman-Sunshine DL, et al. The natural history of persistent peanut allergy. Ann Allergy Asthma Immunol. 2012;108(5):326-331.
3. Vander Leek TK, Liu AH, Stefanski K, Blacker B, Bock SA. The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. J Pediatr. 2000;137(6):749-755.
4. Fleischer DM, et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics. 2012; 130(1):e25-e32.
5. Umasunthar T, et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2013;43(12):1333-1341.
6. Flokstra-de Blok BM, Dubois AE. Quality of life measures for food allergy. Clin Exp Allergy. 2012;42(7):1014-1020.
7. Sova C, et al. Systematic review of nutrient intake and growth in children with multiple IgE-mediated food allergies. Nutr Clin Pract. 2013;28(6):669-675.
8. Gupta R, Holdford D, Bilaver L, Dyer A, Holl JL, Meltzer D. The economic impact of childhood food allergy in the United States. JAMA Pediatr. 2013;167(11):1026-1031.
9. Dunkin D, Berin MC, Mayer L. Allergic sensitization can be induced via multiple physiologic routes in an adjuvant-dependent manner. J Allergy Clin Immunol. 2011;128(6):1251-1258.
10. Frischmeyer-Guerrerio PA, et al. TGF receptor mutations impose a strong predisposition for human allergic disease. Sci Transl Med. 2013; 5(195):195ra194.
11. Zennaro D, et al. Proteomics plus genomics approaches in primary immunodeficiency: the case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Clin Exp Immunol. 2012;167(1):120-128.
12. Man AL, Bertelli E, Regoli M, Chambers SJ, Nicoletti C. Antigen-specific T cell-mediated apoptosis of dendritic cells is impaired in a mouse model of food allergy. J Allergy Clin Immunol. 2004;113(5):965-972.
13. Blazquez AB, Berin MC. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. J Immunol. 2008;180(7):4441-4450.
14. Ganeshan K, Neilsen CV, Hadsaitong A, Schleimer RP, Luo X, Bryce PJ. Impairing oral tolerance promotes allergy and anaphylaxis: a new murine food allergy model. J Allergy Clin Immunol. 2009;123(1):231-238.
15. Yang PC, et al. TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigenspecific Th2 differentiation and intestinal allergy. Gastroenterology. 2007;133(5):1522-1533.
16. Frischmeyer-Guerrerio PA, et al. Dendritic cell and T cell responses in children with food allergy. Clin Exp Allergy. 2011;41(1):61-71.
17. Beyer K, Castro R, Feidel C, Sampson HA. Milkinduced urticaria is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J Allergy Clin Immunol. 2002;109(4):688-693.
18. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergenresponsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199(12):1679-1688.
19. Shreffler WG, Wanich N, Moloney M, Nowak- Wegrzyn A, Sampson HA. Association of allergenspecific regulatory T cells with the onset of clinical tolerance to milk protein. J Allergy Clin Immunol. 2009;123(1):43-52.
20. Ruiter B, Shreffler WG. The role of dendritic cells in food allergy. J Allergy Clin Immunol. 2012;129(4):921-928.
21. Berin MC, Mayer L. Can we produce true tolerance in patients with food allergy? J Allergy Clin Immunol. 2013;131(1):14-22.
22. Kauffmann F, Demenais F. Gene-environment interactions in asthma and allergic diseases: challenges and perspectives. J Allergy Clin Immunol. 2012;130(6):1229-1240.
23. Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy. 2011;66(6):713-724.
24. Ishizaka K, Ishizaka T. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol. 1966;97(1):75-85.
25. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90(2):256-262.
26. Schofield AT. A case of egg poisoning. Lancet. 1908;171(4410):716.
27. Edwards HE. Oral desensitization in food allergy. Can Med Assoc J. 1940;43(3):234-236.
28. Patriarca C, et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol (Madr). 1984;12(4):275-281.
29. Potemkina AM, Timerbaeva GM. [Specific desensitization treatment of children with food hypersensitivity by the sublingual method]. Pediatriia. 1982;(2):38-40.
30. Enrique E, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, doubleblind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073-1079.
31. Yu GP, Weldon B, Neale-May S, Nadeau KC. The safety of peanut oral immunotherapy in peanutallergic subjects in a single-center trial. Int Arch Allergy Immunol. 2012;159(2):179-182.
32. Meglio P, Giampietro PG, Gabriele I, Carello R, Avitabile S, Galli E. Oral desensitisation with food is food-specific and protein-specific. Int J Immunopathol Pharmacol. 2011;24(3):803-811.
33. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy. 2011;41(9):1273-1281.
34. Varshney P, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124(6):1351-1352.
35. Jones SM, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292-300.
36. Hofmann AM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286-291.
37. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. Allergy. 2009;64(8):1218- 1220.
38. Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105(6):444-450.
39. Burks AW, Jones SM. Egg oral immunotherapy in non-anaphylactic children with egg allergy: followup. J Allergy Clin Immunol. 2008;121(1):270-271.
40. Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007;62(11):1261-1269.
41. Patriarca G, et al. Oral specific desensitization in foodallergic children. Dig Dis Sci. 2007;52(7):1662-1672.
42. Buchanan AD, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199-205.
43. Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology. 1998;45(19):52-58.
44. Varshney P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654-660.
45. Blumchen K, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83-91.
46. Itoh N, Itagaki Y, Kurihara K. Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up. Allergol Int. 2010;59(1):43-51.
47. Fleischer DM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119-117.
48. Chin SJ, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol. 2013;132(2):476-478.
49. Kim EH, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640-646.
50. Ojeda P, Ojeda I, Rubio G, Pineda F. Home-based oral immunotherapy protocol with pasteurized egg for children allergic to hen's egg. Isr Med Assoc J. 2012;14(1):34-39.
51. Ruiz Garcia M, Haroun E, Landivar ME, Torres Hernandez JA, Sastre J. Commercial dehydrated egg white for specific oral tolerance induction (SOTI): an easier treatment for egg allergy. J Investig Allergol Clin Immunol. 2012;22(7):529-531.
52. Fuentes-Aparicio V, et al. Oral immunotherapy in hen's egg-allergic children increases a hypo-proliferative subset of CD4+ T cells that could constitute a marker of tolerance achievement. Pediatr Allergy Immunol. 2012;23(7):648-653.
53. Burks AW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233-243.
54. Garcia Rodriguez R, et al. Oral rush desensitization to egg: efficacy and safety. Clin Exp Allergy. 2011;41(9):1289-1296.
55. Vazquez-Ortiz M, et al. Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Clin Exp Allergy. 2013;43(1):92-102.
56. Pajno GB, et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376-381.
57. Staden U, et al. Rush oral immunotherapy in children with persistent cow's milk allergy. J Allergy Clin Immunol. 2008;122(2):418-419.
58. Skripak JM, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2008;122(6):1154-1160.
59. Garcia-Ara C, Pedrosa M, Belver MT, Martin- Munoz MF, Quirce S, Boyano-Martinez T. Efficacy and safety of oral desensitization in children with cow's milk allergy according to their serum specific IgE level. Ann Allergy Asthma Immunol. 2013;110(4):290-294.
60. Alvaro M, et al. Specific oral desensitization in children with IgE-mediated cow's milk allergy. Evolution in one year. Eur J Pediatr. 2012;171(9):1389-1395.
61. Mori F, Pucci N, Rossi ME, de Martino M, Azzari C, Novembre E. Oral desensitization to milk: how to choose the starting dose! Pediatr Allergy Immunol. 2010;21(2 pt 2):e450-e453.
62. Kaneko H, et al. Efficacy of the slow dose-up method for specific oral tolerance induction in children with cow's milk allergy: comparison with reported protocols. J Investig Allergol Clin Immunol. 2010;20(6):538-539.
63. Narisety SD, et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy. J Allergy Clin Immunol. 2009;124(3):610-612.
64. Caminiti L, et al. A new protocol for specific oral tolerance induction in children with IgEmediated cow's milk allergy. Allergy Asthma Proc. 2009;30(4):443-448.
65. Zapatero L, Alonso E, Fuentes V, Martinez MI. Oral desensitization in children with cow's milk allergy. J Investig Allergol Clin Immunol. 2008;18(5):389-396.
66. Meglio P, Giampietro PG, Gianni S, Galli E. Oral desensitization in children with immunoglobulin E-mediated cow's milk allergy - follow-up at 4 yr and 8 months. Pediatr Allergy Immunol. 2008;19(5):412-419.
67. Longo G, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol. 2008;121(2):343-347.
68. Martorell Aragones A, Felix Toledo R, Cerda Mir JC, Martorell Calatayud A. Oral rush desensitization to cow milk. Following of desensitized patients during three years. Allergol Immunopathol (Madr). 2007;35(5):174-176.
69. Morisset M, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. Eur Ann Allergy Clin Immunol. 2007;39(1):12-19.
70. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy. 2004;59(9):980-987.
71. Barbi E, et al. Adverse effects during specific oral tolerance induction: in-hospital "rush" phase. Eur Ann Allergy Clin Immunol. 2012;44(1):18-25.
72. Martorell A, et al. Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy. Clin Exp Allergy. 2011;41(9):1297-1304.
73. de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238-1239.
74. Enrique E, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol. 2008;100(3):283-284.
75. Yeung JP, Kloda LA, McDevitt J, Ben-Shoshan M, Alizadehfar R. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev. 2012;11:CD009542.
76. Keet CA, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448-455.
77. Allam JP, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy. 2008;63(6):720-727.
78. Wessel F, Chartier A, Meunier JP, Magnan A. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX(R)) in a real-life setting for three consecutive seasons - the GRAAL trial. Clin Drug Investig. 2012;32(7):451-463.
79. Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2013;132(3):737-739.
80. Fleischer DM. The natural history of peanut and tree nut allergy. Curr Allergy Asthma Rep. 2007;7(3):175-181.
81. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130(5):1123-1129.
82. Leung DY, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348(11):986-993.
83. Massanari M, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383-389.
84. Kopp MV, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271-279.
85. Casale TB, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134-140.
86. Kuehr J, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274-280.
87. Klunker S, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed- induced allergic rhinitis: Inhibition of IgEfacilitated allergen binding. J Allergy Clin Immunol. 2007;120(3):688-695.
88. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368-1374.
89. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011;127(6):1622-1624.
90. Hemmi H, et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta1-dependent cells. Int Immunol. 2001;13(5):695-704.
91. Akei HS, Mishra A, Blanchard C, Rothenberg ME. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology. 2005;129(3):985-994.
92. Mondoulet L, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy. 2012;2(1):22.
93. Mondoulet L, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophagogastro- enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One. 2012;7(2):e31967.
94. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40(4):659-667.
95. Senti G, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129(1):128-135.
96. Dioszeghy V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen- specific response in sensitized mice. J Immunol. 2011;186(10):5629-5637.
97. Rotiroti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol. 2012;130(4):918-924.
98. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013;131(2):412-420.
99. Senti G, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290- 1296.
100. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71-84.
101. von Moos S, Kundig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011;31(2):391-406.
102. López-Expósito I, Castillo A, Yang N, Liang B, Li XM. Chinese herbal extracts of Rubia cordifolia and Dianthus superbus suppress IgE production and prevent peanut-induced anaphylaxis. Chin Med. 2011;6:35.
103. Qu C, Srivastava K, Ko J, Zhang TF, Sampson HA, Li XM. Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula- 2 is associated with up-regulation of interferongamma. Clin Exp Allergy. 2007;37(6):846-855.
104. Wang J, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol. 2010;105(1):75-84.
105. Li XM, et al. Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol. 2001;108(4):639-646.
106. Patil SP, et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study. J Allergy Clin Immunol. 2011;128(6):1259-1265.
107. Patel D, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103-109.
108. Worm M, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89-97.
109. Yang M, Yang C, Mine Y. Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3- and transforming growth factor-beta-associated mechanisms. Clin Exp Allergy. 2010;40(4):668-678.
110. Swoboda I, et al. A general strategy for the generation of hypoallergenic molecules for the immunotherapy of fish allergy. J Allergy Clin Immunol. 2013;132(4):979-981.
111. Prickett SR, et al. Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy. 2013;43(6):684-697.
112. Li XM, Srivastava K, Huleatt JW, Bottomly K, Burks AW, Sampson HA. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanutinduced anaphylaxis in a murine model. J Immunol. 2003;170(6):3289-3295.
113. Wood RA, et al. A phase 1 study of heat/phenolkilled, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP- 123) for the treatment of peanut allergy. Allergy. 2013;68(6):803-808.
114. Xu W, Tamura T, Takatsu K. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway. Int Immunopharmacol. 2008;8(2):351-361.
115. San Roman B, Irache JM, Gomez S, Gamazo C, Espuelas S. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis. Int Arch Allergy Immunol. 2009;149(2):111-118.
116. Adel-Patient K, Ah-Leung S, Bernard H, Durieux-Alexandrenne C, Creminon C, Wal JM. Oral sensitization to peanut is highly enhanced by application of peanut extracts to intact skin, but is prevented when CpG and cholera toxin are added. Int Arch Allergy Immunol. 2007;143(1):10-20.
117. Kulis M, Gorentla B, Burks AW, Zhong XP. Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. Mol Nutr Food Res. 2013;57(5):906-915.
118. Zhu FG, Kandimalla ER, Yu D, Agrawal S. Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol. 2007; 120(3):631-637.
119. Creticos PS, et al. Immunotherapy with a ragweedtoll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445-1455.
120. Shibata Y, Foster LA, Bradfield JF, Myrvik QN. Oral administration of chitin down-regulates serum IgE levels and lung eosinophilia in the allergic mouse. J Immunol. 2000;164(3):1314-1321.
121. Bae MJ, Shin HS, Kim EK, Kim J, Shon DH. Oral administration of chitin and chitosan prevents peanut-induced anaphylaxis in a murine food allergy model. Int J Biol Macromol. 2013;61:164-168.
122. Liu Y, et al. Blockade of peanut allergy with a novel Ara h 2-Fcgamma fusion protein in mice. J Allergy Clin Immunol. 2013;131(1):213-215.
123. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387-391.
124. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011; 239(1):62-84.
125. Jouvin MH, Kinet JP. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J Allergy Clin Immunol. 2012;130(1):3-10.
126. Traister RS, Green TD, Mitchell L, Greenhawt M. Community opinions regarding oral immunotherapy for food allergies. Ann Allergy Asthma Immunol. 2012;109(5):319-323. Diseases